Business ❯ Pharmaceutical Industry ❯ Drug Development

Clinical Trials

Eli Lilly Market Impact Market Competition Market Analysis Regulatory Approval Market Access Regulatory Affairs FDA Approval FDA Approvals Novo Nordisk Market Approval FDA Regulations Gilead Sciences AstraZeneca Phase II Trials Post-Marketing Activities Lilly Eli Lilly and Co. Mounjaro Impact Immunotherapy Sarepta Therapeutics UGN-102 mRNA Technology Rezurock Innovative Treatments Targeted Therapies Market Regulation Trial Results Merck & Co. Inc. Competition Among Companies Partnerships Vertex Pharmaceuticals Regulatory Approvals Bioavailability AI Integration Insulin Innovations Market Potential Phase 2b Studies Psychedelic Companies Liver Disease Treatment Aduhelm Study AIO-001 Hi1a Drug Market Launch Pfizer's weight-loss pill candidates Mounjaro Market Trends Cytokinetics Cancer Therapies FDA Approval Process Market Challenges Sales Performance Real-World Evidence Phase 3 Trials Amgen Product Recall Psychedelic Research Bayer AG HIV Prevention Drugs Obesity Treatment Regulatory Compliance Zepbound GLP-1 Receptor Agonists Market Research

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

A failed late‑stage readout has forced a program review, plans for major expense reductions, and deep investor reassessment.

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

Pfizer’s Elrexfio Posts Phase 3 PFS Win Over Standard Multiple Myeloma Regimen

FDA Grants Priority Review to Ifinatamab Deruxtecan for Pretreated Small Cell Lung Cancer

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

FDA Opens Safety Review of Infant RSV Antibody Drugs Beyfortus and Enflonsia

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

FDA Outlines 'Plausible-Mechanism' Pathway to Speed Bespoke Therapies

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials